Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05727787 · ClinicalTrials.gov registry record · NA
vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC
A NA study of Liver Cancer, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05727787: Recruiting NA study of Liver Cancer, sponsored by University of Kansas Medical Center.
NCT05727787 is a NA study of Liver Cancer that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 18 participants, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05727787, a NA study of Liver Cancer, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will provide the maximum tolerated dose for radiation therapy for liver tumors and describe the toxicity profile using the vGRID therapy technique. Based on trials using this type of radiation in other cancers demonstrating low toxicity rates even with very high radiation doses and high efficacy, it is likely that vGRID therapy in this trial will be well tolerated and allow dose escalation beyond currently common doses for liver tumors.
Primary Outcome
Safely identify MTD of Single Fraction GRID SBRT and CTCAE v5.0 related toxicity: Irreversible grade 3 hepatotoxicity, grade 4 or 5 hepatotoxicity, grade 4 or 5 gastrointestinal toxicity.
Conditions Studied
Interventions
- RADIATION Stereotactic Body Radiation Treatment
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-02-23 |
| Est. Completion | 2028-08-31 |
| Phase | NA |
What NCT05727787 shows while recruiting
NCT05727787 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic Body Radiation Treatment is the first listed.
NCT05727787 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT05727787 about?
NCT05727787 is a clinical study titled "vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC". This trial will provide the maximum tolerated dose for radiation therapy for liver tumors and describe the toxicity profile using the vGRID therapy technique. Based on trials using this type of radiation in other cancers demonstrating low toxicity rates even with very high radiation doses and high e...
What is the current status of trial NCT05727787?
This trial is currently recruiting. It is a NA study. The enrollment target is 18 participants. The study started on 2023-02-23. Estimated completion is 2028-08-31.
What conditions does trial NCT05727787 study?
This clinical trial studies the following conditions: Liver Cancer.
What interventions are being tested in trial NCT05727787?
The interventions under investigation include: Stereotactic Body Radiation Treatment (RADIATION).
Who is sponsoring clinical trial NCT05727787?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05727787 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05727787's enrollment target sits among peer trials
18 65th of 78 higher than 12 of 78 other Liver Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility Study of CBCT for IGRT in Cancer Patients
RECRUITING · NA
-
Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis
RECRUITING · NA
-
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
RECRUITING · NA
-
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
RECRUITING · NA
-
Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients
RECRUITING · NA
-
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI